Some Standout Approvals In 2015
Some of the notable drug approvals in 2015.
You may also be interested in...
The pace of pharma dealmaking continued unabated in 2015, climaxing with Pfizer’s agreed $160 billion merger with Allergan. Conditions are right for this situation to persist, at least for the foreseeable future.
The health care industry has come a long way in the past 35 years, although in some areas very little has changed. Recently retired In Vivo editor Peter Charlish has seen most of the major developments, and in his final feature, he looks back at some of the big stories in a reporting career that began in the early 1980s.
Less invasive transcatheter techniques will increasingly displace older, riskier open-heart procedures in the treatment of heart valve disease, according to a new Meddevicetracker report. By 2021, transcatheter systems will account for 76% of the global market for heart valve disease treatment products, with the US retaining its current dominant position in this sector.